Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab vs Chemotherapy in R/R cHL
NCT05244642Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of penpulimab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression Free Survival up to 2 years. Started Feb 2022; status: recruiting.
02
Drugs
penpulimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05244642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244642.